JPMorgan Lifts Gilead Sciences, Inc. (GILD)’s Price Target To $145, Maintains Overweight Rating

Gilead Sciences, Inc. (NASDAQ:GILD) is among the Renaissance Technologies Portfolio: 10 Biggest Stocks. On September 16, JPMorgan analyst Chris Schott lifted the stock’s price target to $145 from $135 while maintaining an Overweight rating for its shares.

JPMorgan Lifts Gilead Sciences, Inc. (GILD)'s Price Target To $145, Maintains Overweight Rating

While the firm left most of its large-cap biopharma estimates unchanged, it adjusted share price targets on a move from December 2025 to December 2026.

The adjustment reflects a 29% upside potential for Gilead Sciences, Inc. (NASDAQ:GILD) from its closing share price on September 22.

Overall, Wall Street analysts maintain a positive outlook for the stock, with a consensus Buy rating.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company engaged in the development of medicines to prevent and treat various life-threatening diseases, including HIV, viral hepatitis, and cancer.

READ NEXT: 12 Best Defense Stocks to Buy Right Now and 15 Stocks ChatGPT Predicts Could Make You Wealthy in 5 Years.

Disclosure: None.